DANish Study of Optimal Acute Treatment of Patients With ST-elevation Myocardial Infarction


This study focuses on Cardioprotective strategies.

Full Title of Study: “A Randomised Comparison of the Clinical Outcome After Postconditioning or Deferred Stent Implantation Versus Conventional Treatment”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: February 2016


  • Other: Conventional primary PCI
    • Conventional primary PCI in STEMI with implantation of DES.
  • Other: Ischemic postconditioning.
    • Primary PCI in STEMI with implantation of DES. Following re-opening of the culprit artery mechanical postconditioning with 4 cycles of 30/30 sec. reperfusion/re-occlusion i performed.
  • Other: Deferred stenting in primary PCI.
    • In STEMI re-opening of the artery with guidewire/thrombectomy/small size balloon inflation DES stenting is postponed for 48 hours.

Arms, Groups and Cohorts

  • Active Comparator: Conventional treatment.
    • Conventional primary PCI in STEMI.
  • Experimental: IPost
    • Ischemic postconditioning in STEMI.
  • Experimental: Deferred primary PCI.
    • Deferred strategy in STEMI.

Clinical Trial Outcome Measures

Primary Measures

  • All cause mortality, heart failure (postconditioning)
    • Time Frame: 2 years

Secondary Measures

  • Infarct size in relation to area at risk as determined by MRI after 3 month
    • Time Frame: 3 month
    • Infarct size Salvage index
  • All cause mortality, myocardial infarction, repeat revascularisation and occurrence of definite stent thrombosis according to ARC definition within 1 year (deferred stent strategy)
    • Time Frame: 1 year

Participating in This Clinical Trial

Inclusion Criteria

  • Age ≥ 18 years.
  • Acute onset of chest pain of < 12 hours' duration.
  • ST-segment elevation ≥ 0.1 mV in ≥ 2 contiguous leads, signs of a true posterior infarction or documented newly developed left bundle branch block.

Culprit lesion in a major native vessel.

Exclusion Criteria

  • Pregnancy.
  • Known intolerance of ASA, clopidogrel, heparin or contrast.
  • Inability to understand information or to provide informed consent.
  • Haemorrhagic diathesis or known coagulopathy.
  • Stent thrombosis.

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Rigshospitalet, Denmark
  • Provider of Information About this Clinical Study
    • Principal Investigator: Thomas Engstrom, MD, DMSci, PhD – Rigshospitalet, Denmark
  • Overall Official(s)
    • Lars Koeber, Prof., DMSci, Principal Investigator, The Heart Center, Rigshospitalet, University of Copenhagen
    • Thomas Engstrom, MD, DMSci, Principal Investigator, The Heart Center, Rigshospitalet, University of Copenhagen
    • Henning Kelbaek, MD, DMSci, Principal Investigator, The Heart Center, Rigshospitalet, University of Copenhagen

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.